Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH3 for Prevention of Osteoporosis in Postmenopausal Women
NCT00693667Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2008
- Primary completion
- Jul 2011
- Countries
- 1
- Sponsor
- PhytoHealth Corporation
- Modality
- Small Molecules
- Drugs
- PHN031
- Conditions
- osteoporosis
01
Overview
Phase 2, randomised, double-blind trial of PHN031 in osteoporosis (4 arms), sponsored by PhytoHealth Corporation. Primary endpoint: Biochemical Markers at 4 weeks. Started Feb 2008; status: completed.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Placebo
Placebo tablets
PH3 250 mg
250 mg active ingredient
PH3 500 mg
500 mg active ingredient
PH3 750 mg
750 mg active ingredient
03
Endpoints
Primary
Biochemical Markers
Secondary
Bone Densitometry
Beyond the preview
Go deeper on NCT00693667.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00693667.